Loading...
Docoh

122 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2022 Q2
ANIX Anixa Biosciences Inc
10 Jun 22
Quarterly report
4:22pm
SCHEDULE of SEGMENT INFORMATION
2022202120222021
For the Three Months Ended April 30,For the Six Months Ended April 30,
2022202120222021
Net Loss:
CAR-T Therapeutics$(1,399)$(1,446)$(3,010)$(2,406)
Cancer Vaccines(1,423)(662)(2,780)(1,569)
Anti-Viral Therapeutics(757)(310)(1,661)(791)
Other(9)(19)(16)97
Total$(3,588)$(2,437)$(7,467)$(4,669)
Net loss$(3,588)$(2,437)$(7,467)$(4,669)
Total operating costs and expenses$3,589$2,437$7,469$5,183
Less non-cash share-based compensation(1,681)(1,051)(4,036)(2,037)
Operating costs and expenses excluding non-cash share-based compensation$1,908$1,386$3,433$3,146
Operating costs and expenses excluding non-cash share based compensation:
CAR-T Therapeutics$759$935$1,427$1,492
Cancer Vaccines7402991,220837
Anti-Viral Therapeutics402138774409
Other71412408
Total$1,908$1,386$3,433$3,146
Operating costs and expenses excluding non-cash share based compensation expense$1,908$1,386$3,433$3,146
10-Q
2022 Q2
ANIX Anixa Biosciences Inc
10 Jun 22
Quarterly report
4:22pm
April 30, 2022October 31, 2021
Total assets:
CAR-T Therapeutics$13,014$15,068
Cancer Vaccines12,68013,276
Anti-Viral Therapeutics6,8837,368
Other220545
Total$32,797$36,257
Total Asset$32,797$36,257
10-Q
2022 Q1
PFE Pfizer Inc.
11 May 22
Quarterly report
4:19pm
The following provides detailed revenue information for several of our major products:
(MILLIONS)Three Months Ended
PRODUCTPRIMARY INDICATION OR CLASSApril 3, 2022April. 4, 2021
TOTAL REVENUES(a)$25,661$14,516
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)(a), (b)$25,323$14,125
Vaccines$14,941$4,894
Comirnaty direct sales and alliance revenuesActive immunization to prevent COVID-1913,2273,462
Prevnar family(c)Pneumococcal disease1,5651,284
NimenrixMeningococcal ACWY disease7746
FSME-IMMUN/TicoVacTick-borne encephalitis disease4253
All other VaccinesVarious2949
Hospital(a)$3,191$1,886
PaxlovidCOVID-19 infection (high risk population)1,470
SulperazonBacterial infections210192
ZithromaxBacterial infections12589
Ig Portfolio(d)Various107105
ZaviceftaBacterial infections10494
MedrolAnti-inflammatory glucocorticoid7699
FragminTreatment/prevention of venous thromboembolism7071
VfendFungal infections6580
All other Anti-infectivesVarious381455
All other HospitalVarious583700
Oncology$2,967$2,862
IbranceHR-positive/HER2-negative metastatic breast cancer1,2371,254
Xtandi alliance revenuesmCRPC, nmCRPC, mCSPC268267
InlytaAdvanced RCC234229
Zirabev(e)Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer14786
BosulifPhiladelphia chromosome–positive chronic myelogenous leukemia128123
XalkoriALK-positive and ROS1-positive advanced NSCLC127134
Ruxience(e)Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis12498
Retacrit(e)Anemia115109
SutentAdvanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor114200
LorbrenaALK-positive metastatic NSCLC7260
Bavencio alliance revenuesLocally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC6732
AromasinPost-menopausal early and advanced breast cancer6252
Trazimera(e)HER-positive breast cancer and metastatic stomach cancers5245
BesponsaRelapsed or refractory B-cell acute lymphoblastic leukemia5150
BraftoviIn combination with Mektovi for metastatic melanoma in patients with a BRAFV600E/K mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant mCRC after prior therapy4847
MektoviIn combination with Braftovi for metastatic melanoma in patients with a BRAFV600E/K mutation4035
All other OncologyVarious8141
Internal Medicine$2,440$2,594
Eliquis alliance revenues and direct salesNonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism1,7931,643
Premarin familySymptoms of menopause102143
BMP2Development of bone and cartilage6749
ToviazOveractive bladder5457
Chantix/ChampixAn aid to smoking cessation treatment in adults 18 years of age or older2217
All other Internal MedicineVarious423484
Rare Disease$963$824
Vyndaqel/VyndamaxATTR-cardiomyopathy and polyneuropathy612453
BeneFIXHemophilia B112112
10-Q
2022 Q1
MRNA Moderna Inc
4 May 22
Quarterly report
4:07pm
We use our employee and infrastructure resources for the advancement of our platform, and for discovering and developing programs. Due to the number of ongoing programs and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development programs are generally not recorded or maintained on a program- or modality-specific basis. The following table reflects our research and development expenses, including direct program-specific expenses summarized by modality and indirect or shared operating costs summarized under other research and development expenses during the three months ended March 31, 2022 and 2021 (in millions):
Three Months Ended March 31,
20222021
Program expenses by modality:
Prophylactic vaccines$190$248
Systemic secreted and cell surface therapeutics11
Cancer vaccines317
Intratumoral immuno-oncology66
Systemic intracellular therapeutics45
Inhaled pulmonary therapeutics (1)2
Total program-specific expenses by modality (2)$206$277
Other research and development expenses:
Discovery programs3013
Platform research3425
Technical development and unallocated manufacturing expenses13433
Shared discovery and development expenses13039
Stock-based compensation2014
Total research and development expenses$554$401
10-Q
2022 Q1
ANIX Anixa Biosciences Inc
11 Mar 22
Quarterly report
4:05pm
January 31, 2022October 31, 2021
(in thousands)
Total assets:
CAR-T Therapeutics$15,412$15,068
Cancer Vaccines11,05213,276
Anti-Viral Therapeutics8,5627,368
Other212545
Total$35,238$36,257
Total Asset$35,238$36,257
10-Q
o64t06izgo0ndnw
11 Mar 22
Quarterly report
4:05pm
10-K
fr8v5v zb
25 Feb 22
Annual report
8:07am
10-K
pyerx0
24 Feb 22
Annual report
2:25pm
10-K
o639 7njwm8p
4 Jan 22
Annual report
4:06pm
10-K
344n07fsh3cm ny2zew
4 Jan 22
Annual report
4:06pm
10-Q
j8zyag3 7s
12 Nov 21
Quarterly report
6:06am
10-Q
b9b vob83h
4 Nov 21
Quarterly report
4:48pm
10-Q
7ia3rv
1 Sep 21
Quarterly report
4:46pm
10-Q
dof3gyml
1 Sep 21
Quarterly report
4:46pm
10-Q
tscrsj64eq8l0tso4pmi
5 Aug 21
Quarterly report
4:14pm
10-Q
5afivw1ezi7dr6t3
10 Jun 21
Quarterly report
4:30pm
10-Q
wli86i i8nxdr9
10 Jun 21
Quarterly report
4:30pm
10-Q
99c7q67
13 May 21
Quarterly report
11:32am
10-Q
kdjrf xtegarq7
6 May 21
Quarterly report
4:30pm
10-Q
h0mhap 7p0
11 Mar 21
Quarterly report
4:30pm